International Business Machines Corp vs McKesson Corporation — how do they compare? International Business Machines Corp trades at $226.44 (market cap $213.50B), while McKesson Corporation trades at $930 (market cap $108.46B). The key difference: International Business Machines Corp is the larger of the two by market cap, and International Business Machines Corp pays the higher dividend (2.98%). Which is the better fit depends on your goals — on Pluang, investors hold International Business Machines Corp for 88 Days and McKesson Corporation for 74 Days on average.
| IBM | MCK | |
|---|---|---|
Market Cap | $213.50B | $108.46B |
Volume | 8,908,687 | 712,607 |
Sector | Technology | Health |
52-Week High | $329.23 | $995.69 |
52-Week Low | $205.77 | $725.17 |
Typical Hold Time | 88 Days | 74 Days |
Enterprise Value | $270.64B | $115.00B |
Dividend Yield | 2.98% | 0.4% |
Signals from Pluang's Aura AI — not financial advice
IBM's stock trades at $220.51, down 0.35% on the day, amid a bearish technical signal. The company reported strong 2025 results with revenue of $67.54B and net income of $10.59B, beating earnings expectations in recent quarters. Analyst consensus is a Buy with a $256.69 price target, though technical indicators show resistance near $222. Recent news highlights IBM's focus on AI, including self-hosted deployment for its Bob platform.
IBM presents a mixed outlook with solid fundamentals and AI growth potential offset by near-term technical weakness and competitive pressures. The stock's valuation appears reasonable with a P/E of 19.58, but investors face risks from execution challenges and market volatility. Upside hinges on sustained earnings growth and successful AI integration.
McKesson Corporation (MCK) trades at $910.33, down 1.23% today, but maintains strong analyst support with 80.65% buy ratings and a $956.43 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a major distribution agreement extension with CVS Health through 2032. Revenue growth has accelerated from $264B in 2022 to $359B in 2025, though net margins remain thin at 1.12%.
MCK presents a compelling growth story with consistent earnings outperformance and strategic partnerships driving long-term visibility. However, investors face risks from margin compression, drug pricing pressures, and high leverage with negative shareholder equity. The current valuation at 24.42x P/E appears reasonable given the company's market leadership and oncology growth prospects.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →